According to clinicaltrials.gov, a phase 1 clinical trial was conducted to evaluate the safety and efficacy of autologous nanobody-derived fratricide-resistant CD7 CAR-T cells for patients with relapsed/refractory CD7 + NK/T cell lymphoma, T-lymphoblastic lymphoma (T-LBL), and acute lymphocytic leukemia (ALL) (NCT04004637). This evidence concerns the gene CD7 and acute lymphoblastic leukemia.